Adjunctive immune therapy for fungal infections

Clinical Infectious Diseases

Volumn 33, Issue 7, 2001, Pages 1048-1056

  Casadevall, A ^a   Pirofski, L A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; ANTIFUNGAL ACTIVITY; ASPERGILLUS; BIOTECHNOLOGY; CANDIDA; CLINICAL TRIAL; CRYPTOCOCCUS; DRUG EFFICACY; DRUG INDUCED DISEASE; HISTOPLASMA; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKOCYTE TRANSFUSION; LUNG DISEASE; MYCOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; MYCOSES;

EID: 0035478082     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322710     Document Type: Review

References (118)

1. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis
2. Interleukin-12 in infectious diseases
3. Zygomycosis in the 1990s in a tertiary-care cancer center
4. Aspergillus fumigatus and aspergillosis
5. Cryptococcosis in the era of AIDS - 100 Years after the discovery of Cryptococcus neoformans
6. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals
7. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody
8. Protective murine monoclonal antibodies to Cryptococcus neoformans
9. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection
10. Granulocyte transfusions: Time for a second look
11. Symposium on infectious complications of neoplastic disease. II. Leukocyte transfusions: Thinking twice
12. Neutrophil transfusions: Kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone
13. Granulocyte transfusions: Efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation
14. Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon-γ, and granulocyte-colony-stimulating factor
15. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases
16. Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation
17. Granulocyte colony-stimulating factor-primed leukocyte transfusions in Candida tropicalis fungemia in neutropenic patients
18. Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients
19. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation
20. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed?
21. Cytokines and mycoses
22. Trends in immunotherapy of fungal infections
23. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions
24. Amphotericin-B promotes leukocyte aggregation of nylon-wool-fiber-treated polymophonuclear leukocytes
25. Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: Absence of significant pulmonary toxicity
26. Multiple granulocyte transfusions facilitating successful unrelated bone marrow transplantation in a patient with very severe aplastic anemia complicated by suspected fungal infection
27. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
28. Invasive Aspergillus sinusitis during bone marrow transplantation
29. Neutrophil (granulocyte) transfusions in the new millennium
30. Induction of cellular immunity to Coccidioides immitis after sensitization with dinitrochlorobenzene
31. Chloroquine induces human nonnuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation
32. Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis
33. Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis
34. Adjunctive immunologic therapy for Cryptococcus neoformans infections
35. Diethylcarbamazine-related antimicrobial activity in Mycobacterium tuberculosis-infected blood
36. A comparative review of colony-stimulating factors
37. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
38. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer
39. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients
40. Granulocyte-colony stimulating factor mobilizes T helper 2 inducing dendritic cells
41. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens
42. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens
43. Beneficial effects of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS
44. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony stimulating factor, and surgery: Report of five cases
45. Fungemia in patients with hematologic malignancies: Therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor
46. Disseminated zygomycosis in a neutropenic patient: Successful treatment with amphotericin B lipid complex and granulocytic colony-stimulating factor
47. Role of granulocyte colony-stimulating factor in the treatment of mucormycosis
48. Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy: Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK
49. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae
50. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis
51. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
52. Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: Response to GM-CSF therapy
53. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients
54. Adjuvant therapy with rhGM-CSF for the treatment of Blastoschizomyces capitatus systemic infection in a patient with acute myeloid leukemia
55. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer
56. Localization of transfused neutrophils to site of infection during treatment with recombinant human granulocyte-macrophage colony-stimulating factor and pentoxifylline
57. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony stimulating factor (GM-CSF)
58. Immunorestitution disease involving the innate and adaptive response
59. Use of macrophage colony-stimulating factor in the treatment of fungal infections
60. Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes against Trichosporon asahii
61. Antifungal activity of splenic, liver and pulmonary macrophages against Candida albicans and effects of macrophage colony-stimulating factor
62. The deleterious effect of macrophage colony-stimulating factor (CSF-1) on the pathology of experimental candidiasis in mice
63. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections
64. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor
65. Interferon-gamma and host antimicrobial defense: Current and future clinical applications
66. Cytokines as therapy for opportunistic fungal infections
67. Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease
68. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
69. Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections
70. Disseminated infection with Pseudollescheria boydii in a patient with chronic granulomatous disease: Response to gamma-interferon plus antifungal therapy
71. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis
72. Initiation of T-helper cell immunity to Candida albicans by IL12: The role of the neutrophils
73. Cytokine treatment of central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis
74. Contribution of tumour necrosis factor-alpha (TNF-α) in host defence mechanism against Cryptococcus neoformans
75. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma
76. Interleukin-12 regulation of host defenses against Coccidioides immitis
77. Invaslve fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT)
78. Immunoprophylaxis of bovine dermatophytosis
79. Use of an immunotherpeutic vaccine to treat a life-threatening human arteritic infection caused by Pythium insidiosum
80. Transfer factor
81. Invasive fungal infections in patients with chronic mucocutaneous candidiasis
82. Transfer factor in chronic mucocutaneous candidiasis
83. Immunologic and clinical improvement of progressive coccidioidomycosis following administration of transfer factor
84. Allergic fungal sinusitis: Problems in diagnosis and treatment
85. Treatment of allergic fungal sinusitis: A comparison trial of postoperative immunotherapy with specific fungal antigens
86. In situ hybridization of Aspergillus and Pennicillium in allergic fungal sinusitis: A rapid means of speciating fungal pathogens in tissues
87. Immunotherapy in the treatment of allergic fungal sinusitis
88. The use of glucan as immunostimulant in the treatment of paracoccidiomycosis
89. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor function and IgG subclass
90. Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans
91. Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity
92. Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice
93. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy
94. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
95. Does immune serum globulin confer protection against infectious diseases?
96. Antibody-based therapies for infectious diseases: Renaissance for an abandoned arsenal?
97. Passive antibody therapies: Progress and continuing challenges
98. Return to the past: The case for antibody-based therapies in infectious diseases
99. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies
100. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
101. Antibody response that protects against disseminated candidiasis
102. Antibody immunity and invasive fungal infections
103. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyces dermatitidis
104. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection
105. Immunoglobulin M efficacy against Cryptococcus neoformans: Mechanism, dose dependence and prozone-like effects in passive protection experiments
106. Serum therapy of cryptococcal meningitis
107. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies
108. Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro
109. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity
110. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B
111. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans
112. Autoantibody to heat shock protein 90 can mediate protection against systemic candidosis
113. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis
114. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies
115. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis
116. Effective phagocytosis and killing of Candida albicans via targeting FcγRI (CD64) or FcαRI (CD89) on neutrophils
117. FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy